All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YC1160 | Human anti-TBX3 T cell receptor ((AD3)-1), pCDTCR1 | AD3 | Human | GMGPLLAMV | HLA-A2 | Lentiviral vector | ||
TCR-YC1161 | Human anti-TBX3 T cell receptor ((AD3)-2), pCDTCR1 | Human | AD3 | Human | GMGPLLATV | HLA-A2 | Lentiviral vector | |
TCR-YC1162 | Human anti-TBX3 T cell receptor ((KB3)-1), pCDTCR1 | KB3 | Human | GMGPLLAMV | HLA-A2 | Lentiviral vector | ||
TCR-YC1163 | Human anti-TBX3 T cell receptor ((KB3)-2), pCDTCR1 | Human | KB3 | Human | GMGPLLATV | HLA-A2 | Lentiviral vector | |
TCR-YC1164 | Human anti-TBX3 T cell receptor ((KG4)-1), pCDTCR1 | KG4 | Human | GMGPLLAMV | HLA-A2 | Lentiviral vector | ||
TCR-YC1165 | Human anti-TBX3 T cell receptor ((KG4)-2), pCDTCR1 | Human | KG4 | Human | GMGPLLATV | HLA-A2 | Lentiviral vector | |
TCR-YC1166 | Human anti-TBX3 T cell receptor ((LA8)-1), pCDTCR1 | LA8 | Human | GMGPLLAMV | HLA-A2 | Lentiviral vector | ||
TCR-YC1167 | Human anti-TBX3 T cell receptor ((LA8)-2), pCDTCR1 | Human | LA8 | Human | GMGPLLATV | HLA-A2 | Lentiviral vector | |
TCR-YC1168 | Human anti-TBX3 T cell receptor (LF10), pCDTCR1 | Human | LF10 | Human | GMGPLLATV | HLA-A2 | Lentiviral vector | |
TCR-YC1169 | Human anti-TBX3 T cell receptor (LF4), pCDTCR1 | Human | LF4 | Human | GMGPLLATV | HLA-A2 | Lentiviral vector | |
TCR-YC1170 | Human anti-TBX3 T cell receptor ((SE7)-1), pCDTCR1 | SE7 | Human | GMGPLLAMV | HLA-A2 | Lentiviral vector | ||
TCR-YC1171 | Human anti-TBX3 T cell receptor ((SE7)-2), pCDTCR1 | Human | SE7 | Human | GMGPLLATV | HLA-A2 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION